ImmunityBio’s ANKTIVA Sales Climb 53% As Trial And Commercial Costs Rise
Nine-month product sales reached $143.6 million, while the company plans to seek approval for patients not previously treated with BCG.
ImmunityBio, which sells bladder-cancer immunotherapy ANKTIVA, grew third-quarter product sales 53% to $48.7 million, but its adjusted loss widened to $97.9 million from $72.4 million a year earlier. Monday’s earnings release attributed the sales growth to greater adoption by U.S. urologists and market access, while spending on trials, staff and commercialization increased.
More Prescriptions, Bigger Expenses
ANKTIVA generated $17.0 million more in quarterly net product revenue than a year earlier. For the first nine months of 2026, product sales reached $143.6 million, up 92% from the same period in 2025; full-year 2025 product revenue was $113.0 million.
ImmunityBio President and CEO Richard Adcock said, “We continue to see more physicians prescribing ANKTIVA to multiple patients and growing physician interest in our chemotherapy-free approach in the U.S. and Europe.”
Research and development spending reached $71.5 million, compared with $51.2 million a year earlier. Higher trial and personnel costs outweighed lower manufacturing expenses. Selling and administrative spending rose to $54.0 million from $36.3 million, with professional services, staff and commercial expenses contributing to the increase.
The quarterly loss attributable to common shareholders reached $184.6 million, versus $67.3 million a year earlier, including $77.9 million of non-cash valuation expenses on convertible debt, warrants and derivatives. ImmunityBio attributed those valuation changes mainly to its rising share price during the quarter. Even excluding valuation changes and stock compensation, the adjusted loss increased $25.5 million.
Cash Use Tells A Different Story
For the first nine months, ImmunityBio’s adjusted loss was $265.2 million, compared with $245.0 million a year earlier. That measure also excludes a convertible-note receivable write-off. Research spending for the period rose to $200.3 million from $154.7 million, while selling and administrative expenses increased to $151.6 million from $111.3 million.
Operations consumed $217.2 million in cash over the first nine months, less than the $234.6 million used a year earlier. The quarter alone went the other way: operating cash use reached $75.3 million, versus $68.9 million.
ImmunityBio held $334.3 million in cash, cash equivalents and marketable securities at September 30, 2026. The company develops treatments intended to enlist the immune system against cancer and infectious diseases, with vaccines and natural killer cell therapies also in development.
ANKTIVA’s Eligible Population Expands
The FDA expanded ANKTIVA’s approval on October 14 to include adults with high-grade papillary-only bladder tumors that had not responded to BCG, a standard bladder-cancer treatment. The approval covers ANKTIVA combined with BCG for non-muscle-invasive disease—cancer that has not grown into the bladder’s muscle.
European expansion is also underway. The European Commission granted conditional authorization in February 2026, and ImmunityBio announced initial treatments in Germany and Austria on Wednesday. An Israeli approval obtained with partner Rafa Laboratories brought ANKTIVA’s authorized or approved reach to 35 countries.
ImmunityBio also said its randomized trial in bladder-cancer patients who had never received BCG met its main goal, comparing ANKTIVA plus BCG against BCG alone. That trial addresses a different patient population from the drug’s existing U.S. approval.
ImmunityBio says it remains on track to submit an FDA approval application for ANKTIVA plus BCG in those previously untreated patients in the fourth quarter of 2026.
Sources
- 8-K Filing — ImmunityBio, Inc. (IBRX) — SEC EDGAR
- Exhibit ibrx-2026119x8kexhibit991.htm — ImmunityBio, Inc. 8-K exhibit — SEC EDGAR
- ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings — Yahoo Finance
- ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ — Yahoo Finance
- ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial — businesswire.com
- 8-K filed 2026-10-14 — ImmunityBio, Inc. (earlier disclosure) — SEC EDGAR